Equity Overview
Price & Market Data
Price: $0.879
Daily Change: -$0.0503 / 5.73%
Daily Range: $0.85 - $0.959
Market Cap: $203,448,128
Daily Volume: 1,127,567
Performance Metrics
1 Week: -21.73%
1 Month: -13.04%
3 Months: -20.28%
6 Months: -16.41%
1 Year: -31.67%
YTD: -26.41%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.